New York, May 21, 2024 - PRISM MarketView - Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has received Type C meeting guidance from the FDA regarding the design of its Phase 2b clinical trial. The FDA provided preliminary agreement on Lipella’s overall trial design, including objectives, safety monitoring, control group monitoring, the dosing protocol, the primary efficacy endpoint, and sample size considerations.
The company will evaluate its lead product candidate, LP-10 (liposomal tacrolimus) as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. Lipella has demonstrated preliminary safety and efficacy of LP-10 in a Phase 2a study, which resulted in improved urinary symptoms, including decreased hematuria, decreased cystoscopic bleeding, and a reduced number of ulceration sites.
“We can now proceed with the confidence that our Phase 2b study design can successfully meet its regulatory objectives. This clarity significantly advances our value proposition.”
Lipella’s Chief Medical Officer, Dr. Michael Chancellor
The expected annual revenue per patient for LP-10 is estimated at $20,000 for each intravesical instillation. With a potential market penetration of 50% among the 60,000 patients suffering from hemorrhagic cystitis each year, the revenue opportunity could reach approximately $1.2 billion annually in the U.S. alone.
Hemorrhagic cystitis is a severe, rare and chronic condition often triggered by pelvic radiation therapy and specific chemotherapies, and characterized by significant urinary blood loss. There are currently no FDA approved treatments for moderate to severe hemorrhagic cystitis, a highly morbid and sometimes fatal condition. Lipella’s LP-10 stands at the forefront of addressing this unmet medical need.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, the company maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella recently completed an initial public offering in December 2022. For more information, visit www.lipella.com or LinkedIn for updates.
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
PRISM MarketView
646-863-6341
Prism MarketView | Stock Market News and Investment Opportunities
PRISM MarketView - Social Media (X)